SILEXION THERAPEUTICS CORP
SLXNNASDAQ🏆 #4317 by market capUS Equity
$1.03▼ $0.33 (−32.24%)
Market closed · at close1h—
24h▼ 32.2%
7d▼ 43.1%
14d▼ 38.0%
30d▼ 60.1%
1y▼ 98.6%
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
48
Weak
Trading Snapshot
- Day Range
- $1.02 – $1.05
- 52-Week Range
- $1.45 – $85.90
- Volume
- $4.09B
- Avg Volume
- $4.27B
- Shares Outstanding
- 1.1M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $80,279
- Last Q Revenue
- $22,022
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-55.60
- Dividend Yield
- —
Why Investors Own SLXN
- ✓High-growth profile — revenue up +28.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$80,279▲ +31.3% YoY
Gross Margin (TTM)
37.5%▲ +4.4% YoY
Operating Income (TTM)
$26,894▲ +31.3% YoY
Free Cash Flow (TTM)
$16,457▲ +31.3% YoY
About SILEXION THERAPEUTICS CORP
A company profile for SILEXION THERAPEUTICS CORP isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
48/100
Analyst Price Target
ⓘAverage Target
$1.22
▲ +18.5% Upside
High Target$1.47
Low Target$0.98
Based on 25 analysts
Latest News & Updates
🚀
Reuters·2h ago
SILEXION THERAPEUTICS CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift SLXN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
SILEXION THERAPEUTICS CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.